Evolving role of platelet function testing in coronary artery interventions

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• Dual antiplatelet therapy (aspirin and clopidogrel) is standard for acute coronary syndromes and percutaneous coronary intervention.
• Variable patient responses to clopidogrel have raised concerns, prompting research into pharmacokinetic, pharmacodynamic, and pharmacogenomic factors.
• Platelet function testing, once a research tool, now predicts mortality and guides the development of new antiplatelet agents.

Purpose of the Study:

• To explore the controversy surrounding variable antiplatelet drug response and the role of platelet function testing.
• To identify patient subgroups who may benefit from routine platelet function testing.
• To advocate for individualized antiplatelet therapy using predictive algorithms.

Main Methods:

• Review of existing clinical trials and research on antiplatelet drug response.
• Analysis of the utility of platelet function assays in predicting clinical outcomes.
• Discussion of pharmacogenomic and pharmacodynamic factors influencing antiplatelet efficacy.

Main Results:

• Suboptimal platelet inhibition is linked to adverse cardiovascular, cerebrovascular, and peripheral arterial events.
• Platelet function testing is validated for identifying new drugs and predicting mortality.
• High-risk patients (e.g., diabetes, complex coronary disease, renal failure) may benefit from testing.

Conclusions:

• Platelet function testing may be valuable for guiding antiplatelet therapy in specific high-risk populations.
• Individualized antiplatelet strategies, potentially using platelet function and genetic testing, are needed.
• Further definitive trials are required to establish routine use of platelet function testing.